The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators plan to examine the perioperative use of sufentanil sublingual (SL) in the analgesic regimen for spine surgery, one of the most common surgeries performed in the US. Patients undergoing spinal fusion surgery often experience severe pain during the first three postoperative days. Currently, no data are available for this patient population which routinely experiences moderate to severe acute pain. The investigators will analyze whether sufentanil SL is associated with lower opioid consumption, number of fentanyl boluses given, post-anesthesia care unit and hospital length of stay, side effects of opioid use (i.e., nausea, vomiting, constipation), and hospitalization costs (i.e., pharmacoeconomics).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Analgesics; Sufentanil

Criteria

Inclusion Criteria:

• Patients undergoing spine surgery (> 1 levels)

• Opioid-naïve

• ≥18 years old

• American Society of Anesthesiologists class 1-4

• Planned inpatient stay

Exclusion Criteria:

• Microdiscectomy or single level surgery

• Chronic opiate use

• Liver disease

• Allergy/hypersensitivity to sufentanil

• Patients with baseline dementia

• Plan outpatient surgery